BlackRock
NRXP icon

BlackRock’s NRX Pharmaceuticals NRXP Stock Holding History

BlackRock’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$902K Buy
220,460
+121,465
+123% +$401K ﹤0.01% 4387
2026
Q1 		$211K Buy
98,995
+16,341
+20% +$33K ﹤0.01% 4754
2025
Q4 		$224K Buy
82,654
+17,242
+26% +$46.3K ﹤0.01% 4695
2025
Q3 		$216K Buy
65,412
+1,012
+2% +$2.9K ﹤0.01% 4666
2025
Q2 		$210K Buy
64,400
+35,325
+121% +$88.5K ﹤0.01% 4663
2025
Q1 		$59.6K Hold
29,075
– – ﹤0.01% 4878
2024
Q4 		$64K Hold
29,075
– – ﹤0.01% 4890
2024
Q3 		$49.1K Hold
29,075
– – ﹤0.01% 4816
2024
Q2 		$70.9K Buy
29,075
+4
+0% +$14 ﹤0.01% 4784
2024
Q1 		$137K Hold
29,071
– – ﹤0.01% 4668
2023
Q4 		$134K Hold
29,071
– – ﹤0.01% 4741
2023
Q3 		$75.6K Hold
29,071
– – ﹤0.01% 4913
2023
Q2 		$141K Sell
29,071
-8,454
-23% -$50.8K ﹤0.01% 4827
2023
Q1 		$247K Buy
37,525
+272
+0.7% +$2.76K ﹤0.01% 4717
2022
Q4 		$414K Sell
37,253
-27,601
-43% -$278K ﹤0.01% 4657
2022
Q3 		$480K Sell
64,854
-378
-0.6% -$2.55K ﹤0.01% 4742
2022
Q2 		$391K Buy
65,232
+12,683
+24% +$167K ﹤0.01% 4852
2022
Q1 		$1.29M Buy
52,549
+1,004
+2% +$32.7K ﹤0.01% 4581
2021
Q4 		$2.46M Buy
+51,545
New +$3.72M ﹤0.01% 4322

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock's NRXP Position: Q2 2026 in Review

BlackRock increased its NRX Pharmaceuticals (NRXP) stake by 123% in Q2 2026, buying an estimated $401K and bringing the position to 220,460 shares worth $902K. The position accounts for ﹤0.01% of the portfolio, ranked #4387.

BlackRock first reported a position in NRXP in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.46M in Q4 2021. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • BlackRock held 220,460 shares of NRX Pharmaceuticals worth $902K as of Q2 2026.
  • BlackRock bought 121,465 NRX Pharmaceuticals shares in Q2 2026, an estimated $401K.
  • NRX Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4387 holding.
  • BlackRock first reported a position in NRX Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's NRX Pharmaceuticals position peaked at $2.46M in Q4 2021.
  • 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.